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Purpose: To evaluate the activity of recombinant adenovirus encoding human vasohibin-1 (Ad-Vasohibin-1) on mouse
corneal neovasularization induced by alkali burn.
Methods: For the treatment group, 50 mice each received subconjunctival injection (5 μl) of 109 plaque forming units of
replication-defective Ad-Vasohibin-1. Control group mice received the same dosage of blank adenoviral vector (AdNull).
Five days after injection, corneal neovascularization (CNV) was induced by placing 2.5 μl of 0.1 M NaOH on the right
cornea for 30 s. Subsequently, CNV was observed and photographed every 3 days for a total duration of 9 days after the
alkali burn. The percentage of neovascularized area was measured and compared with the AdNull control. The expression
of human vasohibin-1 protein was detected by immunohistochemistry and western blotting at 5, 8, and 14 days after
injection. The mRNA expression levels of murine vascular endothelial growth factor (Vegf), VEGF receptor 1 and 2
(Vegfr1, Vegfr2), and vasohibin-1 (Vash1) were analyzed and compared by real time quantitative reverse-transcription
polymerase chain reaction.
Results: The percentage of neovascularized area within the cornea was significantly reduced in mice treated with Ad-
Vasohibin-1 compared to mice treated with AdNull at every time point after alkali-induced injury (7.11%±3.91% and
15.48%±1.79% of corneal area in the treatment and control groups, respectively, on day 3; 31.64%±4.71% and 43.93%
±6.15% on day 6, and 45.02%±9.98% and 66.24%±7.17% on day 9, all p<0.001). Human vasohibin-1 protein was detected
at the injection sites on day 3 after corneal burn and was highly expressed in the central subepithelial stroma and co-
localized with neovascularized vessels within the alkali-treated cornea on day 6. On day 9, the peripheral cornea exhibited
a similar staining pattern as the central cornea, but a more intense vasohibin-1 immunostaining signal was detected in the
deep stroma. Some of the vasohibin-1 stain signal diffused into the frontal and deep stroma of the central cornea and was
not co-localized with new vessels. By contrast, in mice injected with AdNull or normal corneas, no vasohibin-1 stain
signal was detected within the corneas. Vasohibin-1 protein expression within treated corneas was also further confirmed
by western blotting on day 5. Expression appeared to peak by day 8 and was maintained at high levels until day 14.
However, Vasohibin-1 protein was not detected in the corneas of normal mice or mice treated with AdNull. Real-time
quantitative reverse-transcription polymerase chain reaction analysis showed that expression of Vegfr2 and endogenous
Vash1 mRNA were significantly decreased in the treatment versus control group (t1=–2.161, p1=0.047; t2=–2.236,
p2=0.041). In contrast, there were no significant differences in Vegf and Vegfr1 mRNA expression levels between the
treatment and control groups (p>0.05 for both).
Conclusions: Subconjunctival injection of Ad-Vasohibin-1 significantly reduces corneal neovascularization in alkali-
treated mouse corneas. This effect of anti-neovascularization may be related to the downregulation of Vegfr2 expression.
Corneal  neovascularization  is  a  severe  debilitating
condition that results in the loss of immune privilege of the
cornea and in visual impairment. It is characterized by corneal
ingrowth of new blood vessels originating from the limbus.
The mechanism of corneal neovascularization is thought to be
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the  result  of  an  imbalance  between  angiogenic  and  anti-
angiogenic  factors  and  the  predominance  of  angiogenic
factors. Angiogenic factors implicated in the development of
corneal  neovascularization  include  vascular  endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF),
leptin, angiogenin, prostaglandins, interleukin-2 and −8, and
platelet-derived  growth  factor  (PDGF)  [1].  Several
angiogenesis  inhibitors  have  also  been  identified  in  the
cornea,  such  as  thrombospondin-1  (TSP-1),  pigment
epithelium-derived factor (PEDF), prolactin, angiostatin, and
endostatin [1].
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1389The regulation of angiogenesis is a complicated process
that involves a series of regulatory switches. Several treatment
modalities are currently used for ocular neovascular diseases,
including  surgery  [2],  laser  photocoagulation  [3],  and
medication [4,5]. However, there are many limitations and
complications  associated  with  each  of  these  treatment
modalities.  Controlling  angiogenesis  by  natural  and/or
synthetic angiogenesis inhibitors might be a promising and
alternative  strategy.  Supplementation  of  exogenous
angiogenesis inhibitors, such as angiostatin [6], endostatin
[7], antithrombin [8], thrombospondin [9], and PEDF [10],
may provide an alterative way to prevent pathological corneal
angiogenesis.
Recently, vasohibin-1 (VASH1) has been identified as a
novel  endothelium-derived  negative  feedback  regulator  of
angiogenesis and is specifically expressed in endothelial cells.
It has been shown to be upregulated in cultured vascular
endothelial cells when stimulated by VEGF and fibroblast
growth factor 2 [11,12]. The major physiologic effects of
vasohibin-1 include inhibition of endothelial cell migration,
proliferation,  and  tube  formation.  Vasohibin-1  has  been
shown  to  suppress  angiogenesis  in  chick  chorioallantoic
membrane after subcutaneous implantation of matrigel, and
in a tumor xenograft model. Overexpression of vasohibin-1
blocks neovascularization in pathological conditions, such as
hypoxia-induced  retinal  ischemia,  and  adventitial
angiogenesis following vascular injury [13,14]. Previously,
Watanabe  and  colleagues  [11]  showed  that  recombinant
vasohibin-1 protein selectively inhibited corneal angiogenesis
in vivo when implanted with bFGF within a mouse corneal
micropocket. We therefore hypothesize that vasohibin-1 gene
transfer may be a useful strategy in the prevention of corneal
neovasularization and may provide a viable future strategy for
suppressing  corneal  neovascularization  under  pathological
conditions.  In  this  study,  we  investigated  the  therapeutic
potential of exogenous recombinant human vasohibin-1 in
inhibiting  corneal  neovascularization  within  alkali-treated
mouse corneas.
METHODS
Construction  of  adenoviral  vector  expressing  human
vasohibin-1:  A  replication-defective  adenoviral  vector
encoding human vasohibin-1 (Ad-Vasohibin-1) was prepared
according  to  our  previous  protocol  [15].  Briefly,  the
Adenovirus Vector Expression kit (TaKaRa, Ohtsu, Japan)
was  used  to  achieve  homologous  recombination  in  vivo
between  the  transfer  cassette  bearing  the  vasohibin-1
expression unit and the adenovirus genome as well as the
restriction enzyme-digested adenovirus genome tagged with
terminal protein in human embryonic kidney (HEK) 293 cells.
Plaque-purified adenoviruses were propagated in HEK 293
cells. The viral lysates were purified and concentrated through
two  cycles  of  CsCl2  step  gradients.  The  reconstructed
adenovirus was divided into several aliquots and stored at a
titer of 1.0×109 pfu (plaque forming unit)/μl at –80 °C. The
adenoviral vector without the encoding gene (AdNull) was
used as the negative control.
Animals: The research protocol was approved by the animal
care  committee  of  Zhongshan  Ophthalmic  Center
(Guangzhou, China). The animals were handled and fed in
accordance with the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic  and  Vision  Research.  For  the  alkali-induced
corneal  neovascularization  assay,  female  BALB/c  mice
(Guangdong  Provincial  Center  for  Animal  Experiment,
Guangzhou City, Guangdong Province, China) were used. A
total of 110 mice, aged 6–8-weeks old, with weight ranging
from 18 to 20 g were used for this study. Mice with corneal
scars or neovascularization were excluded from this study.
Subconjunctival injection of adenovirus: One hundred out of
a total of 110 mice were randomly assigned to the treatment
or control groups. In the treatment group, 50 mice received
subconjunctival injection of 5 μl of viral solution containing
109 viral particles of Ad-Vasohibin-1. In the control group, 50
mice received subconjunctival injection of the same amount
of AdNull. Only the right eye of each mouse was used for
injection.  The  remaining  ten  mice  were  used  as  normal
controls without injection.
Induction of alkali burn-induced corneal neovascularization:
Five  days  after  subconjunctival  injection,  corneal
neovascularization was induced by alkali burn, according to
the  method  devised  by  Ormerod  and  collegues  with
modification [16]. Briefly, after general anesthesia with an
intraperitoneal  injection  of  a  combination  of  xylazine
hydrochloride (5 mg/kg) and ketamine hydrochloride (35 mg/
kg; both purchased from HangZhou Peak Chemical Corp.,
Zhejiang, China), and topical anesthesia with a drop of 0.5%
proparacaine hydrochloride (Alcaine eye drops; Alcon Inc.,
Fort  Worth,  TX),  filter  paper  (2.5  mm  diameter)  was
immersed in 2.5 μl 0.1 M NaOH and then placed centrally on
the mouse cornea for 30 s. The alkali-treated cornea was then
irrigated with 60 ml of normal saline. Subsequently, corneal
and limbal epithelia were scraped off with a surgical blade
under a microscope. Erythromycin ophthalmic ointment was
administered immediately after epithelial denudation.
The area of corneal neovascularization was quantified by
photographic documentation every 3 days for a total duration
of 9 days. Three mice of each group were sacrificed on days
3, 6, and 9 after corneal injury for immunohistochemistry.
Corneas from ten mice of each group were procured on days
5, 8, and 14 after alkali treatment for western blot analysis.
On day 9 after alkali treatment, corneas from the remaining
mice  were  procured  for  real-time  quantitative  reverse
transcription PCR (RT–PCR) analysis.
Quantification of corneal neovascularization: On days 3, 6,
and 9 after alkali-induced corneal injury, murine corneas were
examined with a digital camera (ORCA ER; Hamamatsu,
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The  images  were  captured  by  ImageNet  2000  software
(Topcon Medical Systems Inc., Oakland, NJ). The National
Institutes  of  Health  (NIH)  Image  J1.62  software  was
subsequently  used  for  quantitative  image  analysis  [17]
(developed by Wayne Rasband, NIH, Bethesda, MD). The
vascularized area was outlined using the innermost vessel of
the limbal arcade as the border. The area of neovascularization
was normalized to the entire cornea, and the percentage of
corneal  neovascularization  was  calculated.  Calculation  of
CNV  (Corneal  Neovascularization)  percentages  was
performed in a masked fashion.
Real-time  quantitative  reverse-transcription  polymerase
chain reaction: Nine days after the alkali burn, corneas were
dissected and RNA samples were isolated using an RNeasy
kit (QIAGEN, Valencia, CA). After quantification of the RNA
concentration, total RNA was treated with DNase I (Ambion,
Austin, TX) to remove any contaminated genomic DNA. One
microgram of murine total RNA per 20 μl of reaction volume
was reverse transcribed into cDNA using the SuperScript III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA).
Minus  RT  (diethylpyrocarbonate  [DEPC]-treated  water
instead of transcriptase when making cDNA) and nontemplate
control samples were made at the same time as controls for
quantitative  real-time  PCR  amplification.  Samples  of
synthesized cDNA were divided into aliquots and stored at –
80 °C.
Real-time quantitative PCR was performed and analyzed
using  an  ABI  PRISM  7000  sequence  detection  system
(Applied  Biosystems  Inc.,  Foster  City,  CA).  The  relative
quantitative method was used to determine gene expression
levels, as described in detail by Bookout et al. [18,19]. The
standard curve method was used for relative quantification of
the gene of interest (GOI), such as Vash1, Vegf, and VEGF
receptor  1  and  2  (Vegfr1  and  Vegfr2),  relative  to
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Each
sample was run in triplicate, and a dilution series of standard
cDNA samples was constructed for the GOI and reference
gene (Gapdh). Reactions were performed in a 20-μl volume
using the SYBR Green reaction mix (QIAGEN) with 0.5
mmol/l primers and 2 μl cDNA. The sequences of the PCR
primer pairs are listed in Table 1. Thermal cycling consisted
of denaturation for 10 min at 95 °C, followed by 40 cycles of
30 s at 95 °C and 1 min at 60 °C.
For analysis, the method of linear regression was applied.
The linear regression formula was produced by plotting the
Ct (threshold cycle) versus the log nanogram (log ng) of the
input standard purified Gapdh cDNA. The formulas resulting
from  the  standard  curves  were  used  to  interpolate  the
quantities of GOI and reference gene in the unknown samples.
For each of the three replicates of a single sample, the average
quantity (avg) of target cDNA interpolated from the standard
curve, the standard deviation of the average (stdev), and the
coefficient  of  variation  (CV)  according  to  the  formula
CV=stdev/avg  were  calculated.  After  removal  of  outlier
points  (>17%  CV),  the  avg,  stdev,  and  CV  values  were
recalculated.  Only  one  outlier  point  per  replicate  was
removed. For each sample, the GOI quantity was normalized
to that of the Gapdh gene as arbitrary units (AU), according
to  the  following  equation:  normalized  value=avg  GOI
quantity/avg reference quantity.
Immunofluorescent  staining  for  human  vasohibin-1:  For
immunofluorescent staining, three eyes of BALB/c mice in
each group were enucleated at each of the preset time points,
fixed  in  10%  (volume/volume)  neutralized  formaldehyde
solution, and embedded in paraffin according to established
tissue harvesting protocols [11]. Five sections were made in
each tissue block. Immunofluorescent staining was performed
using  a  standard  indirect  fluorescent  staining  method,  as
previously  described  [11].  Briefly,  the  dewaxed  and
rehydrated  sections  were  pretreated  at  90  °C  in  a  buffer
solution  (antigen  retrieval  solution;  DAKO,  Glostrup,
Denmark). Subsequently, the sections were incubated with
8%  (v/v)  normal  donkey  serum  for  30  min  at  room
temperature  to  block  unspecific  binding.  After  briefly
washing, the samples were reacted with rabbit antihuman
antibody, which specifically recognizes human vasohibin-1
(dilution factor of 1:300) and with rat antimouse CD31 (anti-
PECAM;  dilution  factor  of  1:150;  BD  PharMingen,  San
Diego, CA) overnight at 4 °C to assess localization of the
endothelium  of  corneal  neovascular  vessels.  The  samples
were then washed and incubated with either donkey antirabbit
polyclonal  Immunoglobulin  (IgG)  antibody  conjugated  to
Cy3 (1:1,000; Jackson ImmunoResearch Laboratories, West
Grove, PA) or donkey antirat IgG conjugated with Fluorescein
Isothiocyanate (FITC) for 1 h at room temperature in the dark.
Subsequently after washing with PBS (pH 7.4, 137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4), the
TABLE 1. PRIMER SETS FOR REAL TIME RT–PCR.
Gene Forward (5′-3′) Reverse (5′-3′)
Vash1 AGACGCCACTGTCGCTTT TGTCTTTGGAACTTTGTCTGCAA
Vegf CAGGCTGCTGTAACGATGAA AATGCTTTCTCCGCTCTGAA
Vegfr1 GAGGAGGATGAGGGTGTCTATAGGT GTGATCAGCTCCAGGTTTGACTT
Vegfr2 GCCCTGCCTGTGGTCTCACTAC CAAAGCATTGCCCATTCGAT
Gapdh CTCATGACCACAGTCCATGC CACATTGGGGGTAGGAACAC
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Aldrich Corp., St. Louis, MO) and viewed under a Nikon
fluorescence microscope. For controls, primary antibody was
eliminated from the staining procedure.
Western blot analysis for human vasohibin-1 expression: The
expression  levels  of  human  vasohibin-1  protein  in  mouse
corneas were evaluated by western blot analysis. Ten corneal
samples were procured from each group on days 5, 8, and 14
after  subconjunctival  injection  and  immediately  stored  in
liquid nitrogen. Corneal samples were homogenized with a
pre-cooled mortar and pestle, pooled together, and placed in
lysis buffer containing 50 mmol/l Tris·HCl (pH 7.4), 150
mmol/l NaCl, 1% deoxycholic acid, 0.1% sodium dodecyl
sulfate (SDS), and 0.5% nonyl phenoxylpolyethoxylethanol
(NP-40), with Complete Protease Inhibitor Cocktail (Cat No.
11697498001;  Roche,  Mannheim,  Germany).  Protein
concentrations were determined by the micro-bicinchoninic
acid (BCA) assay (Cat No. 23235; Pierce Inc., Rockford, IL),
following  the  manufacturer’s  instructions.  Twenty
micrograms of protein were loaded in wells of a 10% SDS gel.
After electrophoresis, separated proteins were transferred to
a  nitrocellulose  membrane.  The  membrane  was  then
incubated in 0.05 mol/l Tris-buffered saline, pH 7.6 (TBS)
containing  5%  (weight/volume)  skimmed  milk  to  block
nonspecific binding and then incubated in TBS containing
0.05%  Tween-20,  2.5%  skim  milk,  and  0.5  μg/ml  mouse
antihuman  vasohibin-1  monoclonal  antibody.  After  three
washes with TBS–Tween-20, the membrane was incubated in
horseradish  peroxidase-conjugated  rabbit  antimouse
polyclonal antibody (1:5,000; Amersham-Pharmacia Biotech,
Piscataway,  NJ).  For  signal  detection,  Enhanced
Chemoluminescence-Plus western blotting detection reagent
(Amersham-Pharmacia Biotech) was used. Membranes were
exposed to Kodak Biomax films (Kodak Inc., Rochester, NY).
Statistical analysis: Statistical analysis was performed with
the  SPSS  software  for  Microsoft  Windows  (version  17.0;
SPSS Inc., Chicago, IL). Values were reported as mean±SD
(standard deviation). Each eye was treated as an independent
event  for  statistical  analysis  of  corneal  vessels.  One-way
ANOVA (ANOVA) and the Student’s t-test for independent
samples were used for assessing differences in the percentages
of CNV and relative levels of gene expression (normalized
values) between the treatment and control groups at the same
time  point.  A  p  value  <0.05  was  considered  statistically
significant.
RESULTS
Reduction of neovascularization within alkali-treated mice
corneas  after  subconjunctival  injection  of  recombinant
adenovirus encoding VASH1: The vascularized area after the
alkali  burn  was  quantified  to  evaluate  the  effect  of  Ad-
Vasohibin-1  on  corneal  neovascularization.  During  the
experiment, two mice in the treatment group and three mice
in the control group died from an overdose of anesthesia
before the first time point. The percentages of neovascularized
cornea (area) from the treatment and control groups were
7.11%±3.91%  (n=38)  and  15.48%±1.79%  (n=37),
respectively, on day 3, 31.64%±4.71% (n=25) and 43.93%
Figure  1.  The  percentages  of
neovascularized  cornea  at  each  time
point.  The  percentage  of
neovascularized cornea increased over
time in both groups but was significantly
reduced  in  mice  with  subconjunctival
injection  of  recombinant  adenovirus
encoding human Vasohibin-1 gene (Ad-
Vasohibin-1) compared with the blank
adenoviral vector (AdNull) at all time
points  after  alkali-induced  injury.  On
day 3, there was statistical difference in
the  percentage  of  CNV  area  between
Ad-Vasohibin-1  (n=38)  and  Ad  Null
(n=37)  groups  (F=50.26,  t=–11.940,
95% CI of the difference: –9.78% to –
6.80%). The same results were obtained
on  day  6  between  Ad-Vasohibin-1
(n=25)  and  Ad  Null  (n=24)  groups
(F=3.953,  t=–7.868,  95%  CI  of  the
difference: –15.42% to –9.14%) and on
day 9 between Ad-Vasohibin-1 (n=22)
and Ad Null (n=21) groups (F=2.318,
t=–7.975, 95% CI of the difference: –
26.60%  to  –15.85%).  The  asterisk
indicates a p<0.01.
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1392±6.15% (n=24), respectively, on day 6, and 45.02%±9.98%
(n=22) and 66.24%±7.17% (n=21), respectively, on day 9.
Hence, the percentages of neovascularized cornea increased
over time in both groups but was significantly reduced in mice
with subconjunctival injection of Ad-Vasohibin-1 compared
to the AdNull control at every time point after alkali-induced
injury (all p<0.001; Figure 1). Corneal neovascularization was
therefore  significantly  reduced  by  treatment  with
subconjunctival injection of Ad-Vasohibin-1 (Figure 2).
Expression of exogenous human vasohibin-1 within alkali-
treated  mice  corneas  after  subconjunctival  injection:  The
expression of human vasohibin-1 protein was analyzed by
fluorescent immunostaining of excised corneas from both the
treatment and control groups. We used a specific antibody that
recognizes  human  vasohibin-1  protein,  as  well  as  rat
antimouse CD31 antibody to detect the endothelial cells of
neovascularized vessels. On day 3 after alkali-induced injury,
vasohibin-1 was detected at the injection sites. On day 6, it
was highly expressed within the central subepithelial stroma
and  was  co-localized  with  neovascularized  vessels  in  the
cornea. On day 9, a similar staining pattern to that observed
in the central cornea was displayed by the peripheral cornea,
but a more intense vasohibin-1 immunostaining signal was
observed in the deep stroma. Some of the vasohibin-1 protein
diffused into the frontal and deep stroma of the central cornea
and was not co-localized with new blood vessels of the cornea.
In contrast, the corneas of normal mice without injection of
Ad-Vasohibin-1  and  corneas  with  injection  of  AdNull
displayed negative immunostaining for vasohibin-1 (Figure
3).
Western blot analysis was then performed to compare the
expression of human vasohibin-1 protein in the treated and
control mice. As shown in Figure 4, the expression of human
vasohibin-1 protein in corneas was initially detected on day 5
(time point of alkali-induced corneal injury), subsequently
increased to the peak level on day 8, and was maintained at
high levels until day 14 after subconjunctival injection of Ad-
Vasohibin-1.  However,  no  expression  of  the  protein  was
detected in the corneas of normal mice and mice injected with
AdNull.
Effect of exogenous vasohibin-1 on the expression of vascular
endothelial growth factor, vascular endothelial growth factor
receptor-1, vascular endothelial growth factor receptor-2 and
endogenous vasohibin-1 in alkali-treated mice corneas: Real-
time quantitative RT–PCR was performed to determine the
expression of Vegf and its receptors (Vegfr1, Vegfr2) as well
as  endogenous  Vash1  between  the  treatment  and  control
groups (Figure 5). The target genes were normalized relative
to  the  standard  housekeeping  gene  (Gapdh).  To  compare
relative  expression  between  groups,  all  values  for
quantification of target gene expression were normalized as
AU,  as  described  in  the  Methods  section.  The  mRNA
expression  level  of  Vegfr2  and  endogenous  Vash1
significantly decreased in the treatment group (5.80±3.83,
181.08±108.92 AU, respectively) compared to the control
group  (14.66±11.66,  657.23±630.91  AU,  respectively;
Vegfr2,  F-ratio=4.672,t-value=–2.161,p-value=0.047,95%
Confidence Interval: –17.61 to –0.12; Vash1, F-ratio=4.999,
t-value=–2.236,p-value=0.041,95%  Confidence  Interval:–
930.07  to  –22.23).  In  contrast,  there  were  no  significant
Figure 2. Corneal neovascularization in alkali-treated mice. The area of neovascularized cornea increased over time in both the experimental
and control groups but was significantly reduced in mice treated with subconjunctival injection of Ad-Vasohibin-1 (A–C) compared to the
control group with AdNull (D–F) on day 3 (A, D), day 6 (B, E), and day 9 (C, F) after alkali-induced injury.
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1393differences  in  the  expression  levels  of  Vegf  between  the
treated and control mice (8.17±6.28 versus 80.29±135.38,
respectively,  F-ratio=19.77, t-value=–1.603,   p-
value=0.130,95% Confidence Interval: –168.02 to 23.78) and
Vegfr1  (113.85±145.94  versus  206.73±263.29,  F-
ratio=0.844,t-value=–0.914,p-value=0.375,95%  Confidence
Interval:–309.41 to 123.66; p>0.05 for both genes).
Figure 3. The expression of exogenous human vasohibin-1 protein in mouse corneas at different time points after alkali-induced injury. Ad-
Vasohibin-1 was injected subconjunctivally 5 days before alkali-induced corneal injury at a titer of 109 viral particles. A–C: On day 3 after
alkali-induced injury (8 days after injection), vasohibin-1 was expressed within the injection sites and some staining signals were detected at
the roots of the iris. D–F:On day 6 after alkali treatment, vasohibin-1 was highly expressed in the subepithelial stroma of the cornea, and some
immunostaining was detected in the deep stroma of the central cornea. Vasohibin-1 expression was highly co-localized with corneal
neovascularzation. Immunostaining was diffusely distributed in the frontal stroma, which was not co-localized with new blood vessels within
the cornea. G–I: On day 9, peripheral cornea showed a similar staining pattern as central cornea, but more vasohibin-1 expression was detected
in the deep corneal stroma. J–L: There was no positive    immunostaining  for  vasohibin-1  and  CD31  antigen  in normal cornea without
subconjunctival injection.
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Corneal neovascularization alters visual acuity and is induced
by  inflammatory,  infectious,  ischemic,  degenerative,  or
traumatic diseases of the cornea and loss of the limbal stem
cell barrier. This major ocular complication also results in loss
of  the  immune-privileged  status  of  the  cornea,  thereby
worsening  the  prognosis  of  subsequent  penetrating
keratoplasty. Several clinical studies have shown that corneal
neovascularization is the main risk factor of corneal transplant
rejection [20], and for highly neovascularized cornea, the
rejection rate has been reported as high as 50%. Angiogenesis
is an extremely complicate process that is related to vascular
endothelial cells. It is a prerequisite that vascular endothelial
cells proliferate and migrate to form capillary tubes during
angiogenesis. Hence, many therapeutic strategies for anti-
angiogenesis involve blocking or inhibiting these processes.
Several angiogenesis inhibitors have been investigated for
medical  treatment,  including  prolactin  [21],  somatostatin
[22], and thalidomide [23]. Recently, targeted angiostatin and
endostatin  gene  transfer  [24,25]  has  been  attempted  as  a
means to halt angiogenesis in a mouse tumor model.
As  previous  studies  have  shown,  overexpression  of
VEGF, bFGF, PDGF, nitric oxide synthases, angiopoietin,
and angiopoietin 2 were detected in alkali-burned corneas as
early as 3 days [1]. VEGF is a key mediator of angiogenesis,
and anti-VEGF therapies have been demonstrated to strongly
suppress  corneal  neovascularization  [26,27].  Even  though
anti-VEGF single chain antibody has shown some promise for
the treatment of angiogenic-related diseases, such as age-
related  macular  degeneration  and  tumor  angiogenesis,
effective  endogenous  anti-angiogenic  molecules  still  have
superb application prospects because they will not interfere
with survival pathways.
In  this  study,  we  selected  vasohibin-1,  which  is  well
known  to  have  an  anti-angiogenic  effect  on  vascular
endothelial cells in vitro and investigated whether vasohibin-1
gene delivery can inhibit corneal neovascularization in an in
vivo  model.  Our  results  demonstrate  that  transfer  of
recombinant  adenovirus  encoding  vasohibin-1  obviously
Figure  4.  Expression  of  vasohibin-1
protein  within  mouse  cornea,  as
detected by western blot analysis. Mice
were administered with subconjunctival
injection of Ad-Vasohibin-1 at 109 viral
particles.  Corneas  were  harvested  at
different  time  points,  and  protein
samples  were  extracted.  Ten  corneal
samples were pooled together for each
western  blot  analysis.  A  mouse
antihuman  vasohibin-1  monoclonal
antibody was used for the western blot.
No vasohibin-1 western blot signal was
detected  before  Ad-Vasohibin-1  was
injected. A relatively weak signal was
detected on day 5 and was maintained at
high levels until day 14 after injection.
Figure  5.  Quantitative  comparison  of
gene expression between the treatment
and  control  groups  by  real  time  RT–
PCR.  The  transcript  quantification  of
target genes was normalized relative to
the  standard  housekeeping  gene
encoding Gapdh (arbitrary units, AU).
The  expression  of  Vegfr2  and
endogenous  Vash1  mRNA  transcripts
were  significantly  decreased  in  the
treatment group compared to the control
group (A, B). Meanwhile, there were
slightly  decreased  but  no  significant
differences in the expression levels of
Vegf and Vegfr1 (C, D) in the treatment
versus control group (p>0.05 for both
genes).
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1395suppressed corneal neovascularization in vivo. The inhibition
of  corneal  neovascularization  is  associated  with  a  robust
expression  of  exogenous  human  vasohibin-1,  which  is
detected not only in the endothelial cells of newly formed
blood vessels but also within the corneal stroma as a soluble
protein.  This  could  possibly  indicate  that  endothelial
progenitor cell recruitment into the cornea was reduced.
As was reported previously [11-14], vasohibin-1 can act
in  a  negative  feedback  loop  to  help  suppress
neovascularization within an experimental tumor transplant
model,  a  retinal  neovascularization  model,  and  a  corneal
micropocket model. However, the results of our study showed
that  the  anti-angiogenic  effect  exhibited  by  vasoinhibin-1
appears  to  be  VEGF  independent  and  not  mediated  by
suppression of VEGF. The level of Vegf mRNA expression
was almost the same in both the treatment and control groups.
The inhibition of corneal neovascularization was associated
with  suppression  of  Vegfr2  but  not  Vegfr1  expression  by
exogenous vasohibin-1 signaling. This may be achieved by
either inhibiting the expression or enhancing the degradation
of  Vegfr2  mRNA.  The  same  result  was  also  observed  in
cultured endothelial cells in vitro [14] and in animal models
with retinal neovascularization [13], whereby suppression of
Vegfr2 but not Vegfr1 reduced the ability of VEGF to induce
vasohibin-1. Basic FGF is another major factor implicated in
the induction of corneal angiogenesis and has been reported
to exert a more potent effect compared to VEGF at the same
dosage  [28].  FGF  function  is  mediated  by  binding  to  its
cognate receptor. In a previous study by Sato and colleagues,
vasohibin-1  protein  inhibited  corneal  neovascularization
induced  by  bFGF.  However,  it  is  unknown  whether
vasohibin-1 will also have an effect on either the expression
or binding of FGF receptors.
Vasohibin  inhibits  growth,  migration,  and  network
formation by endothelial cells. It has two homologs, vasohibin
1 and 2 [29], both of which are expressed in endothelial cells.
The expression pattern of vasohibin-2 in vivo resembles that
of  vasohibin-1  but  is  generally  at  a  lower  level  than
vasohibin-1 expression and unaffected by stimulation that
normally induces vasohibin-1. Vasohibin-2 was previously
shown to exhibit anti-angiogenic activity like vasohibin-1 in
a mouse corneal micropocket assay when implanted together
with bFGF [30]. In this study, only vasohibin-1 cDNA was
incorporated  within  an  adenovirus  and  injected
subconjunctivally  into  the  eyes  of  mice.  Vasohibin-1
functions through two isoforms of 42 and 36 kDa that are
processed by proteolytic cleavage at a site close to the mutated
residues, which include the carboxyl terminal basic domain
that  possesses  activities  for  heparin  binding  and  anti-
angiogenesis [30]. A previous study showed that vasohibin-1
could be a downstream effecter of protein kinase C-delta
(PKC-δ)  in  endothelial  cells,  which  regulate  angiogenesis
inhibition [31]. In any case, the underlying mechanism of the
anti-angiogenic effect of vasohibin-1 has not yet been fully
characterized. However, it is unlikely to work antagonistically
against VEGF, as shown in this study. Additional studies are
needed to elucidate the mechanism by which vasohibin-1
works and find ways to utilize its anti-angiogenic activity for
the treatment of corneal diseases.
As shown in the results, endogenous vasohibin-1 was
downregulated with lesser corneal neovascularization but was
not  detected  in  normal  corneas.  This  implies  that  the
expression of vasohibin-1 is associated with the appearance
of corneal neovascularization and suggests that vasohibin-1
may  not  be  an  important  determining  factor  of  corneal
avascularity. The avascularity of the cornea is required for
optical clarity and optimal vision. The most crucial factor
discovered  to  date  in  maintaining  corneal  avascularity  is
soluble VEGF receptor-1 [32], which is required to prevent
neovascularization.  Several  other  mechanisms  may  also
contribute  to  corneal  avascularity,  such  as  the  angiostatic
nature of corneal epithelial cells, low levels of pro-angiogenic
matrix metalloproteinases (MMPs), several anti-angiogenic
factors—including  pigment  epithelium-derived  factor  and
tissue inhibitor of metalloproteinases—as well as the barrier
function of limbal cells [33]. In any case, the mechanisms
underlying the maintenance of corneal avascularity remain
poorly understood. Currently, no single factor has yet been
identified to be critically responsible for maintaining corneal
avascularity.
Gene therapy has great potential in treating ocular surface
diseases related to cornea because of its accessibility and
immune privileged status. Various routes of administration of
the target gene have been investigated in experimental studies
to test the feasibility of gene transfer to the ocular surface
tissues.  Intracameral  delivery,  intrastromal  application,
topical  eyedrops,  and  subconjunctival  injection  have  all
demonstrated encouraging results [34]. However, except for
topical  and  subconjunctival  administration,  all  other  gene
delivery strategies to the cornea are invasive and result in the
damage  of  corneal  integrity.  Major  determinants  for  the
success of gene therapy are the use of a novel vector and new
gene delivery techniques. In our animal model, recombinant
replication-defective  adenovirus  vector  was  used.  Alkali-
induced corneal angiogenesis was successfully reduced by
subconjunctival injection of Ad-Vasohibin-1. The results thus
demonstrated  that  replication-defective  adenovirus  vector
could provide a highly efficient gene delivery system for
ocular surface gene therapy. The recombinant adenovirus was
successfully  transferred  into  corneal  cells,  such  as
keratocytes,  and  produced  targeted  protein.  However,  the
duration  of  recombinant  target  gene  expression  by  an
adenoviral vector is limited (around 1 month), according to
previous studies [11-14]. In our study, a high expression level
of  vasohibin-1  was  observed  from  day  5  onwards,  and
expression was maintained at high levels up to day 14 after
administration, but expression gradually declined afterwards.
As a result, the current approach of using an adenoviral vector
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1396may not always be useful for clinical therapy of chronic or
slowly progressing degenerative diseases.
Ad-Vasohibin-1  significantly  reduced  corneal
neovascularization in the alkali-treated animal model. We
observed that Ad-Vasohibin-1 successfully transduced mouse
cornea.  A  diffused  distribution  of  vasohibin-1  protein
expression extending over the cornea was acquired in the
alkali-treated mouse cornea. The transgene usually switches
on 5 days after adenoviral gene transduction. However, we
could  not  obtain  an  anti-angiogenic  effect  when  Ad-
Vasohibin-1 was injected at the day of corneal alkali burn
(data not show). This may be due to the lagging expression of
the transferred gene and its lower efficiency of transduction
in the damaged keratocytes of burned cornea than in normal
cornea before an alkaline burn.
In summary, we demonstrated that topical application of
adenovirus encoding human vasohibin-1 has potent inhibitory
effects on the progression of corneal neovascularization in
vivo. Therefore, vasohibin-1 therapy may be useful as an
angiogenic regulator for treating corneal diseases that exhibit
neovascularization.
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